A phase II study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma (nccRCC)

被引：0
|
作者：
Hutson, Thomas E.
Michaelson, M. Dror
Kuzel, Timothy M.
Agarwal, Neeraj
Molina, Ana M.
Hsieh, James J.
Vaishampayan, Ulka N.
Xie, Sharon
Bapat, Urmi
Jain, Rohit K.
Fishman, Mayer N.
机构：
[1] Texas A&M HSC Coll Med, Dallas, TX USA
[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[3] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[4] Huntsman Canc Ctr, Salt Lake City, UT USA
[5] Weill Med Coll, New York, NY USA
[6] Washington Univ, Sch Med St Louis, St Louis, MO 63110 USA
[7] Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[8] Eisai Inc, Woodcliff Lake, NJ USA
[9] Canc Ctr South Florida, Tampa, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
685
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma
    Hutson, Thomas E.
    Michaelson, M. Dror
    Kuzel, Timothy M.
    Agarwal, Neeraj
    Molina, Ana M.
    Hsieh, James J.
    Vaishampayan, Ulka N.
    Xie, Ran
    Bapat, Urmi
    Ye, Weifei
    Jain, Rohit K.
    Fishman, Mayer N.
    [J]. EUROPEAN UROLOGY, 2021, 80 (02) : 162 - 170
  • [2] A phase 2 trial of lenvatinib in combination with everolimus in patients with advanced or metastatic non-clear cell renal cell carcinoma
    Hutson, Thomas
    Xing, Dongyuan
    Dutcus, Corina
    Baig, Mahadi
    Fishman, Mayer
    [J]. BJU INTERNATIONAL, 2016, 118 : 14 - 15
  • [3] Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma
    Voss, Martin H.
    Molina, Ana M.
    Chen, Ying-Bei
    Woo, Kaitlin M.
    Chaim, Joshua L.
    Coskey, Devyn T.
    Redzematovic, Almedina
    Wang, Patricia
    Lee, William
    Selcuklu, S. Duygu
    Lee, Chung-Han
    Berger, Michael F.
    Tickoo, Satish K.
    Reuter, Victor E.
    Patil, Sujata
    Hsieh, James J.
    Motzer, Robert J.
    Feldman, Darren R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (32) : 3846 - +
  • [4] Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC).
    Mckay, Rana R.
    McGregor, Bradley Alexander
    Gray, Kathryn
    Steinharter, John A.
    Walsh, Meghara K.
    Braun, David A.
    Flaifel, Abdallah
    VanAllen, Eliezer
    Wei, Xiao X.
    Signoretti, Sabina
    Harshman, Lauren Christine
    Vaishampayan, Ulka N.
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) plus lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)
    Albiges, L.
    Gurney, H. P.
    Atduev, V.
    Suarez, C.
    Climent Duran, M. A.
    Pook, D.
    Tomczak, P.
    Barthelemy, P.
    Lee, J-L.
    Nalbandian, T.
    Stus, V.
    Ferguson, T.
    Wiechno, P.
    Gokmen, E.
    Lacombe, L.
    Gedye, C.
    Perini, R.
    Sharma, M.
    Li, C.
    Lee, C-H.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1204 - S1204
  • [6] Non-clear cell renal cell carcinoma (nccRCC): A Brazilian experience.
    Yamamura, Rosely
    Rinck, Jose A.
    Fonseca Jesus, Victor Hugo
    Tavares, Monique Celeste
    de Castro Larclprete, Ana Luisa
    Iennaco, Pietro Schettlni
    Freitas, Heleno C.
    Cunha, Isabela Warneck
    Fanelli, Marcello Ferretti
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).
    Laramee, Sophie
    Ghosh, Sunita
    Kollmannsberger, Christian K.
    Hansen, Aaron Richard
    Wood, Lori
    Soulieres, Denis
    Canil, Christina M.
    Saleh, Ramy
    Castonguay, Vincent
    Bjarnason, Georg A.
    Basappa, Naveen S.
    Breau, Rodney H.
    Heng, Daniel Yick Chin
    Pouliot, Frederic
    Kapoor, Anil
    Lalani, Aly-Khan A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [8] A phase II trial of everolimus and bevacizumab in advanced non-clear cell renal cell cancer.
    Voss, Martin Henner
    Chen, Yingbei
    Chaim, Joshua
    Coskey, Devyn Taylor
    Woo, Kaitlin
    Patil, Sujata
    Molina, Ana M.
    Hsieh, James
    Motzer, Robert J.
    Feldman, Darren Richard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [9] Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma
    Lee, J. -L.
    Ahn, J. -H.
    Lim, H. Y.
    Park, S. H.
    Lee, S. H.
    Kim, T. M.
    Lee, D. -H.
    Cho, Y. M.
    Song, C.
    Hong, J. H.
    Kim, C. -S.
    Ahn, H.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (08) : 2108 - 2114
  • [10] Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Safety and efficacy from CheckMate 920.
    Tykodi, Scott S.
    Gordan, Lucio N.
    Alter, Robert S.
    Arrowsmith, Edward
    Harrison, Michael Roger
    Percent, Ivor John
    Singal, Rakesh
    Van Veldhuizen, Peter J.
    George, Daniel J.
    Hutson, Thomas E.
    Zhang, Joshua
    Zoco, Jesus
    Johansen, Jennifer L.
    Kalebasty, Arash Rezazadeh
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345